Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE

The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG’s Xarelto blood-thinner as a cost-effective way to prevent strokes in people with an irregular heartbeat known as atrial fibrillation.

Deciding whether to start treatment with the drug should be made after the patient and physician have discussed Xarelto’s risks and benefits compared with warfarin, an older treatment, the health-cost agency, known as NICE, said today in an e-mailed statement.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.